LifeTech Scientific Corporation (1302) AI Stock Analysis

• Market Cap: HK$8.42B
• Dividend Yield: N/A
• Average Volume (3M): 45.05M
• Price to Earnings (P/E): 109.5
• Beta (1Y): 0.95
• Revenue Growth: 3.42%
• EPS Growth: -70.82%
• Country: HK
• Employees: 1,395
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Devices
• EPS (TTM): 0.01
• Shares Outstanding: 4,631,712,400
• 10 Day Avg. Volume: 44,160,900
• 30 Day Avg. Volume: 45,046,746
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$2.50
• Price Target Upside: 28.21% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 73 Outperform
• Price Target: HK$2.50 ▲(28.21% Upside)

LifeTech Scientific Corporation's stock is supported by strong technical momentum and a solid financial foundation. However, high valuation and inconsistent cash flow generation present risks. Addressing operational efficiencies and cash flow stability could enhance long-term performance.

LifeTech Scientific Corporation Business Overview & Revenue Model

Company Description

LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The company operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. Its products include LAmbre left atrial appendage closure systems, as well as CeraFlex, Cera, Heart, and Konara-MF VSD occluders; Ankura thoracic aortic aneurysm and abdominal aortic aneurysm stent graft systems; delivery systems, such as Fustar steerable and SteerEase introducers; Aegisy vena cava filters; Cera vascular plug systems; AcuMark sizing balloons; LawMax dilators; and SeQure snare systems, as well as pacemakers. The company is also involved in the biomedical research and development; manufacturing and trading of materials for hemp; staff training and internal personnel management business; information consulting for investors; and manufacturing and trading of medical devices, as well as technical, consulting, and technology services. It has operations in Mainland China, India, rest of Asia, Europe, South America, Africa, and internationally. LifeTech Scientific Corporation was founded in 1999 and is headquartered in Shenzhen, the People's Republic of China.

How the Company Makes Money

LifeTech Scientific Corporation generates revenue through the sale of its medical devices, which are primarily used in interventional procedures to treat cardiovascular and neurovascular diseases. The company's revenue streams include direct product sales to hospitals and healthcare providers, as well as distribution agreements with partners in different regions. Additionally, LifeTech invests in research and development to innovate and expand its product offerings, which helps maintain a competitive edge in the market. Partnerships with international medical device companies and healthcare institutions also play a role in expanding its market presence and driving sales growth.

LifeTech Scientific Corporation Financial Statement Overview

Summary

LifeTech Scientific Corporation demonstrates strong revenue growth and maintains a healthy balance sheet with low leverage. However, declining margins and inconsistent cash flow generation pose challenges that could affect long-term sustainability. The company should address operational efficiencies and cash flow stability to enhance financial performance.

Income Statement

LifeTech Scientific Corporation shows strong revenue growth with a notable increase from 2019 to 2024. The gross profit margin remains robust, indicating efficient cost management and strong competitive positioning. However, a declining EBIT margin from 2023 to 2024 suggests increased operational costs, impacting profitability. The net profit margin has slightly decreased over the years, indicating some pressure on bottom-line growth.

Balance Sheet

The company's balance sheet is solid with a low debt-to-equity ratio, suggesting minimal leverage risk. The equity ratio is high, indicating strong capitalization and stability. However, the slight decrease in return on equity (ROE) suggests that profitability relative to shareholders' equity is under pressure, which can be a concern if it continues.

Cash Flow

Free cash flow has been inconsistent, with significant fluctuation over the years. The operating cash flow to net income ratio is not available for the latest period, making assessment difficult. The company must focus on stabilizing its free cash flow to support future investments and growth.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.30B	1.27B	1.10B	925.33M	642.30M
Gross Profit	981.43M	995.64M	873.93M	747.53M	513.14M
EBITDA	271.87M	253.46M	445.78M	397.59M	133.30M
Net Income	222.39M	263.24M	325.34M	292.47M	216.09M
Balance Sheet
Total Assets	4.90B	4.70B	3.69B	3.18B	2.95B
Cash, Cash Equivalents and Short-Term Investments	1.18B	1.18B	833.79M	1.48B	1.14B
Total Debt	4.98M	9.30M	9.67M	15.67M	185.98M
Total Liabilities	1.42B	1.37B	769.05M	653.61M	596.06M
Stockholders Equity	3.49B	3.37B	2.90B	2.50B	2.34B
Cash Flow
Free Cash Flow	38.46M	125.36M	52.84M	145.57M	180.15M
Operating Cash Flow	321.46M	418.05M	388.32M	488.85M	338.53M
Investing Cash Flow	-517.53M	-453.88M	-458.47M	-86.76M	-341.63M
Financing Cash Flow	-116.97M	182.71M	-215.20M	-256.38M	674.66M

LifeTech Scientific Corporation Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.95
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1302, the sentiment is Neutral. The current price of 1.95 is below the 20-day moving average (MA) of 2.10, below the 50-day MA of 1.98, and above the 200-day MA of 1.63, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 42.88 is Neutral, neither overbought nor oversold. The STOCH value of 8.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1302.

LifeTech Scientific Corporation Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1302	73 Outperform	HK$8.42B	109.55	1.98%	―	3.42%	-70.82%
Sector *	51 Neutral	$7.85B	-0.21	-41.41%	2.22%	22.81%	-2.01%
MCRPF	―	$2.89B	―	-31.45%	―	―	―
818	―	€833.47M	41.06	4.99%	―	―	―
2172	66 Neutral	HK$7.64B	34.53	11.79%	1.45%	-5.18%	-9.69%
2160	51 Neutral	HK$3.26B	613.64	0.22%	―	-4.38%	―
6606	―	HK$6.47B	―		―	―	―

LifeTech Scientific Corporation Corporate Events

LifeTech Scientific Boosts Electrophysiology Portfolio with Strategic Investment in Affector Medtech

LifeTech Scientific Corporation has announced a strategic investment in Affector Medtech, a high-tech company in China specializing in electrophysiology and innovative medical devices. The investment, totaling RMB150 million, will be executed in stages and will grant LifeTech a 30% equity interest in Affector Medtech. This move is expected to enhance LifeTech’s capabilities in cardiac intervention imaging and electrophysiology, with exclusive cooperation and distribution rights for Affector’s products. The partnership aims to foster joint research and development, leveraging both companies’ strengths to advance in the medical device market.

LifeTech Scientific Secures Shareholder Approval for Key Resolutions at AGM

LifeTech Scientific Corporation announced that all proposed resolutions were successfully passed by shareholders during the Annual General Meeting held on May 28, 2025. The resolutions included the adoption of financial statements, re-election of directors, and authorization of share issuance and repurchase mandates, indicating strong shareholder support and strategic continuity for the company.

LifeTech Scientific Announces Board Committee Changes

LifeTech Scientific Corporation has announced a change in the composition of its board committee, effective May 23, 2025. Ms. Ruan Xingmei and Mr. Wang Wansong have been appointed as members of the Nomination Committee, which now includes five members with Mr. Zhou Luming as chairman. This change is expected to enhance the governance and strategic decision-making processes within the company.

LifeTech Scientific Announces Board Composition and Roles

LifeTech Scientific Corporation has announced the composition of its board of directors, highlighting the roles and functions of its executive, non-executive, and independent non-executive directors. This announcement underscores the company’s commitment to maintaining a robust governance structure, which is crucial for its strategic operations and industry positioning.

LifeTech Scientific’s Aortic Arch Stent Graft System Gains China NMPA Approval

LifeTech Scientific Corporation has announced the official registration approval from the China National Medical Products Administration for its Aortic Arch Stent Graft System, a pioneering product aimed at aortic arch branch reconstruction using the fenestration technique. This approval marks a significant milestone in the company’s product portfolio, enhancing its position in the peripheral vascular intervention field. The system, which includes the Ankura™ Plus and CSkirt™ components, demonstrated high success rates and safety in clinical studies, and is expected to provide a comprehensive and effective solution for aortic dissection lesions. The launch is anticipated to drive further development and commercialization of innovative medical devices, benefiting a wide range of patients.